Technology platforms of SynDermix
SynDermix AG is a Swiss developer of innovative health technologies funded by private investors. The Company focuses on the development of effective and safe treatments that meaningfully respect patient convenience and that address important unmet medical needs. Currently, 35% of the company is (indirectly) owned by ESGTI.
An electronic medical device platform based on Precisely Modulated Acoustic Energy (PMAE) therapy, which is capable of non-invasively targeting internal tissues with accuracy, fast onset of action, efficacy and safety. (Most advanced product in clinical stage of development.)
A platform based on an endogenous nitric oxide (NO) donor in an easy-to-use formulation, which solves the challenges of releasing and stabilising NO locally for therapeutic use. (Preclinical stage of development.)
A drug platform based on a novel recombinant plant lectin with positive Phase IIa results in epithelial healing. (Preclinical stage of development.)